Wachstumshormon
IGF-1 LR3
Anaboler Effektor
Long-acting IGF-1 analogue with 20–30h half-life. Activates mTORC1, suppresses FOXO atrophy genes, and drives satellite cell proliferation. 1000× reduced IGFBP binding vs native IGF-1.
Aminosäuren83
Mol. Gewicht9117 Da
Halbwertszeit20–30 Stunden
Verfügbarkeit
✅ Auf Lager
Aminosäuresequenz
Modified IGF-1 with N-terminal Met extension + Arg3 substitution
What Is IGF-1 LR3?
IGF-1 LR3 is a recombinant analogue of endogenous IGF-1 with two modifications: N-terminal methionine extension and glutamic acid→arginine (R3) substitution. The R3 change reduces IGFBP binding affinity >1000×, extending half-life from ~12 minutes to 20–30 hours.
Schlüsselmechanismen
- PI3K→Akt→mTORC1 — phosphorylates S6K1 and 4E-BP1, driving ribosomal biogenesis and protein translation
- Ras→MEK→ERK — cell cycle progression (G1→S via cyclin D1), DNA replication, differentiation
- FOXO suppression — phosphorylates FOXO1/3a, blocking MuRF1 and Atrogin-1 transcription — prevents muscle proteolysis
- Satellite cell activation — drives skeletal muscle stem cell proliferation and myofibre formation
Wichtige Referenzen
- Coleman ME et al. “IGF-I stimulates muscle cell differentiation and myofiber hypertrophy.” J Biol Chem, 1995;270:12109–12116.
- Foulstone EJ et al. “Role of IGFBP-3 in the IGF axis of human skeletal muscle.” J Cell Physiol, 2003;196:229–240.